Novartis CEO's Optimism on Sales Growth and Patent Protection
Insights on Novartis' Sales Growth
In a recent interview, Novartis CEO Vas Narasimhan expressed strong confidence regarding the pharmaceutical giant's sales performance, forecasting a growth of at least 5% annually until 2028.
Addressing Patent Protection Challenges
- The expiration of patents on several drugs, including Entresto, is not seen as a detrimental factor.
- Narasimhan emphasized the importance of maintaining a pipeline of innovative medications.
Despite fears that the pharmaceutical industry may face declining sales due to patent cliffs, Narasimhan remains confident, highlighting the prospects of several multi-billion dollar sales drugs.
Future Plans and Profitability
- Anticipated growth in profit for 2025.
- A commitment to acquisitions, particularly smaller, strategic deals.
While the core operating profit margin may stabilize around 40.1%, Novartis is focused on growth through research and development.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.